Rechargeable Implantable Thin-Film Lithium Battery

描述（由申请人提供）：电池供电的可植入系统现在广泛用于治疗和假肢应用，如心脏起搏器/除颤器，药物泵，以及最近用于帕金森病，疼痛缓解，中耳植入和耳蜗植入的神经刺激器。对于大多数此类应用，目前可用电池的能量密度和寿命不足以实现完全植入式系统，并且电池经常保持在外部。在第二阶段，前沿技术（FET）建议继续开发一种先进的可充电电池，用于完全植入式听力修复装置，如耳蜗植入物和中耳植入物。相对于最先进的可充电电池，该电池具有三倍的能量密度，三倍的电池寿命和一半的充电时间。在第二阶段，FET将以一种新颖的方式通过堆叠高能量密度的第一阶段电池来生产高容量电池，从而保持整体的高能量密度。将生产足够数量的电池，以支持大型耳蜗植入制造商和植入式电池制造商进行广泛的内部测试和评估。在第一阶段之前，FET成功地展示了(I)超高能量密度单层电池（800Wh/L） （ii）非常长的循环寿命（bbb4000次循环）和（iii）相对快速的充电（6分钟）。拟议的商业应用：我们最初的电池将设计用于耳蜗植入，目前耳蜗植入的年销售额约为4.25亿美元，预计每年将增长约20%。在完成人工耳蜗示范电池后，我们将继续研究其他植入式神经调节应用，这些应用目前的年销售额为16亿美元，预计在10到15年内将增长到100亿美元。除了神经调节应用，我们的电池技术将适用于助听器的可充电电池，目前估计这是一个价值50亿美元的产业。主题词：植入式医疗电源，薄膜电池，锂电池，人工耳蜗，神经刺激器电源，神经调节植入电池，助听器电池。

DESCRIPTION (provided by applicant): Battery-powered implantable systems are now being used in a wide array of therapeutic and prosthetic applications such as cardiac pacemakers/defibrillators, drug pumps, and more recently, neurostimulators for Parkinsons, pain relief, middle-ear implant and cochlear implant. For most of these applications, the energy-density and life of currently-available batteries are insufficient to enable fully-implantable systems and the battery frequently remains external. In Phase II, Front Edge Technology (FET) proposes to continue the development, it commenced in Phase I, of an advanced rechargeable battery for fully implantable hearing prosthetics devices such as cochlear implants and middle-ear implants. Relative to the state- of-the-art rechargeable batteries, the proposed battery has three times the energy density, three times the battery life and half the recharge time. During Phase II, FET will produce high capacity batteries by stacking high energy density Phase I cells in a novel manner such that overall high energy density is maintained. Sufficient quantities of batteries will be produced to support extensive in-house testing and evaluation by both a major cochlear-implant manufacturer and an implantable battery manufacturer. Previously in Phase I, FET successfully demonstrated (i) ultra-high energy density single layer cells (800Wh/L) (ii) very long cycle life (> 4000 cycles) and (iii) relatively fast recharge (6 minutes). Proposed Commercial Applications: Our initial battery will be designed for cochlear implants, which have current annual sales of approximately $ 425 million and expected to grow by approximately 20% annually. Upon completion of the cochlear demonstration battery, we will pursue the other implantable neuromodulation applications, which have current annual sales of $1.6 billion and expected to grow to $10 billion in 10 to 15 years. In addition to neuromodulation applications, our battery technology will be suitable for rechargeable batteries for hearing aids, currently estimated to be a $5 billion dollar industry. Thesaurus Terms: Implantable medical power source, thin-film battery, lithium battery, cochlear implant, neurostimulator power source, neuromodulation implant battery, hearing aid battery.